blog

Looking back over the past year, it is gratifying as CEO to reflect on the extraordinary progress we’ve made at Umoja Biopharma.   This year has had no shortage of major accomplishments for the company. Topping the list is our recent closing of an oversubscribed $210 million Series B funding round. We view our success […]